<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499368</url>
  </required_header>
  <id_info>
    <org_study_id>LAF-BR-CT-302</org_study_id>
    <nct_id>NCT01499368</nct_id>
  </id_info>
  <brief_title>A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing rate of erosive esophagitis</measure>
    <time_frame>8 weeks</time_frame>
    <description>Healing rate of erosive esophagitis after 8 weeks based on the baseline</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>Lafutidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lafutidine 20mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Famotidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Famotidine 40mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Omeprazole 20mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lafutidine</intervention_name>
    <description>Lafutidine 20mg/day</description>
    <arm_group_label>Lafutidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Famotidine 40mg/day</description>
    <arm_group_label>Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole 20mg/day</description>
    <arm_group_label>Omeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux
             esophagitis according to the Los Angeles classification

        Exclusion Criteria:

          -  Gastric or duodenal ulcers (excluding ulcer scars)

          -  Concurrent presence of Barrett's esophagus

          -  A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks

          -  Other conditions considered by the attending physician to potentially affect the
             assessment of efficacy and safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Woo Lee</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
    <mesh_term>Lafutidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 16, 2018</submitted>
    <returned>February 12, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

